chronic myelogenous leukemia

Also found in: Dictionary, Thesaurus, Financial, Acronyms, Encyclopedia, Wikipedia.

chronic myelocytic leukemia

a heterogeneous group of myeloproliferative disorders that may evolve into acute leukemia in late stages (that is, blast crisis.)

chronic myelogenous leukemia

Leukemia characterized by abnormally high levels of granulocytes in the blood and bone marrow and by the presence in most of these cells of an abnormal chromosome (the Philadelphia chromosome), occurring primarily in older adults and typically having a slow progression with early symptoms including fatigue and an enlarged spleen. Also called chronic granulocytic leukemia, chronic myelocytic leukemia, chronic myeloid leukemia.

chronic myelogenous leukemia

Myeloproliferative neoplasm characterized by the unregulated and excessive production of cells of the myelocytic maturation series and presence of the BCR/ABL 1 mutation. Compare acute lymphocytic leukemia, chronic lymphocytic leukemia, leukemoid reaction. See also acute myelocytic leukemia, chronic myelocytic leukemia, leukocytosis.

chron·ic my·e·lo·cyt·ic leu·ke·mi·a

(kron'ik mī'ĕ-lō-sit'ik lū-kē'mē-ă)
A heterogeneous group of myeloproliferative disorders that may evolve into acute leukemia in late stages (i.e., blast crisis). Slow onset, usually in olderadults.
Synonym(s): chronic granulocytic leukemia, chronic myelogenous leukemia, chronic myeloid leukemia.

Chronic myelogenous leukemia (CML)

Also called chronic myelocytic leukemia, malignant disorder that involves abnormal accumulation of white cells in the marrow and bloodstream.
References in periodicals archive ?
STI571 or Imatinib mesylate: Inhibits proliferation and induces apoptosis by inhibiting tyrosine kinase activity in cells positive for BCR/ABL and fresh leukemic cells in chronic myelogenous leukemia (CML) that is positive for the Ph chromosome (7)
Tyrosine Kinase Inhibitors of Bcr-Abl in Chronic Myelogenous Leukemia Characteristic Imatinib Targets Bcr-Abl tyrosine kinases Response rates Complete cytogenetic response occurred in more than 80% of patients in early chronic phase; in accelerated and blast phases, 76% and 34% had hematologic remissions.
Otherwise, his medical history was significant for Philadelphia chromosome-positive chronic myelogenous leukemia, which had been treated with oral imatinib.
NEW ORLEANS -- If the experimental drug STI-571 turns out to be as good as it sounds, standard treatment for chronic myelogenous leukemia and other hematologic malignancies may soon be as simple as taking a pill every day.
The 168 patients studied included persons with advanced-stage acute or chronic myelogenous leukemia or acute lymphocytic leukemia who had had 1 or more relapses, those with lymphomas refractory to treatment, and individuals with myelodysplasias.
The medicine is authorised in Europe for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia, who have previously received one or more tyrosine kinase inhibitors and who are considered inappropriate for treatment options such as imatinib, nilotinib and dasatinib.
The medicine has received approval for the treatment of adults with chronic, accelerated, or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML), which has not responded to earlier therapy.
Being alert to the potential development of such problems in patients with underlying myeloproliferative diseases such as chronic myelogenous leukemia or myelofibrosis might prevent unnecessary surgery.
The medicine known commercially as Gleevec serves as a powerful weapon for people fighting the blood cancer called chronic myelogenous leukemia, or CML.
Gleevec was designed to treat chronic myelogenous leukemia, a blood cancer affecting about 20,000 people in the United States.

Full browser ?